Jazz Pharmaceuticals Inc.
Jazz Pharmaceuticals Inc. is listed today as Jazz Pharmaceuticals plc: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jul 2009 | $7 M | Private placement after listing | $2 to $10 million | equity, options | SEC | |
| Mar 2008 | $120 M | Private placement after listing | $50 to $250 million | debt, options | SEC | |
| Jun 2005 | $80 M | No. 1 | $50 to $250 million | debt, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Jazz Pharmaceuticals plc, its revenue in fiscal 2025 came from these product and service lines: Product sales, net $4.02 billion (94%), Total Neuroscience $2.88 billion (67%), Xywav $1.66 billion (39%), Total Oncology $1.13 billion (26%), Epidiolex/Epidyolex $1.06 billion (25%).
Annual report (SEC XBRL) · Dec 2025
Jazz Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2009).
SEC Form D · Nov 2009
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Jul 2009
Products and services#
No products or services of Jazz Pharmaceuticals Inc. are on record.
Investors#
No investor of Jazz Pharmaceuticals Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 12 investors.
Largest shareholders today
Institutions holding Jazz Pharmaceuticals plc shares, as of Sep 30, 2026.
- BlackRock, Inc.$1.5 B10.06%
- FMR LLC$1.3 B8.64%
- Vanguard Portfolio Management LLC$711 M4.79%
- Vanguard Capital Management LLC$649 M4.37%
- Capital World Investors$554 M3.73%
- LSV Asset Management$495 M3.33%
- State Street Corp$479 M3.22%
- Franklin Templeton Inc$450 M3.03%
- Geode Capital Management, LLC$355 M2.39%
- Dimensional Fund Advisors LP$336 M2.26%
- Fuller & Thaler Asset Management, Inc.$324 M2.18%
- AQR Capital Management LLC$272 M1.83%
- Ameriprise Financial Inc$270 M1.82%
- Bank Of America Corp /de/$262 M1.76%
- Citadel Advisors LLC$248 M1.67%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Bruce C. Cozadd | Executive officer | Nov 2009 |
| Carol A. Gamble | Executive officer | Nov 2009 |
| Janne L.T. Wissel | Executive officer | Nov 2009 |
| Joan E. Colligan | Executive officer | Nov 2009 |
| Robert M. Myers | Executive officer | Nov 2009 |
| Bruce Cozzad | Executive officer | Jul 2009 |
| Alan M. Sebulsky | Director | Nov 2009 |
| Bruce C. Cozadd | Director | Nov 2009 |
| Bryan C. Cressey | Director | Nov 2009 |
| James B. Tananbaum | Director | Nov 2009 |
| James C. Momtazee | Director | Nov 2009 |
| Kenneth W. O'Keefe | Director | Nov 2009 |
| Michael W. Michelson | Director | Nov 2009 |
| Nathaniel M. Zilkha | Director | Nov 2009 |
| Patrick G. Enright | Director | Nov 2009 |
| Robert M. Myers | Director | Nov 2009 |
| Samuel D. Colella | Director | Nov 2009 |
| Michael W. Michaelson | Director | Nov 2009 |
| Brian C. Cressey | Director | Jul 2009 |
| Bruce Cozzad | Director | Jul 2009 |
| E. Alexander Albert | Director | Jul 2009 |
About
Irish tax-registered pharmaceutical corporation.
Went public since 2007. Its SEC number is that of a company listed on a stock exchange.